2016 AUGUST

The topic of the month focuses on transporter expression in chronic liver diseases. There is growing evidence regarding the role of liver diseases on transporter expression. Interestingly, liver imaging may be used to assess transporter dysfunction in liver diseases (PubMed 1 and PubMed 2). Publications in 2015 and 2016 as well as reviews in 2014, 2013, and 2012 are included. Keywords in PubMed: Transporters and liver diseases.

  • J Clin Pharmacol. 2016;56 Suppl 7:S205-21. Effect of disease pathologies on transporter expression and function. Atilano-Roque A, Roda G, Fogueri U, Kiser JJ, Joy MS. This review focuses on uptake and efflux transporter proteins in liver, kidney, and brain and discusses mechanisms of altered transporter expression and function secondary to disease. PubMed
  • Mol Pharm. 2016;13:2691-701. 20. Effect of intestinal flora on protein expression of drug-metabolizing enzymes and transporters in the liver and kidney of germ-free and antibiotics-treated mice. Kuno T, Hirayama-Kurogi M, Ito S, Ohtsuki S. PubMed
  • Adv Drug Deliv Rev. 2016 in press. Loops and layers of post-translational modifications of drug transporters. Xu D, You G. This review article summarizes the recent advances in identifying the posttranslational modifications underlying the regulation of SLC drug transporters. PubMed
  • Drug Saf. 2016 Jul;39:589-611. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal Impairment. Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. PubMed
  • Chem Res Toxicol. 2016;29:545-63. Involvement of drug transporters in organ toxicity: The fundamental basis of drug discovery and development. Cheng Y, El-Kattan A, Zhang Y, Ray AS, Lai Y. The authors describe transporter associated diseases and organ toxicities resulting from transporter gene deficiency or functional inhibition in the liver, kidney, gastrointestinal tract, and central nervous system. PubMed
  • Pharm Sci. 2016;105:106-12. IMAGING. Influence of 24-nor-ursodeoxycholic acid on hepatic disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography study in mice. Wanek T, Halilbasic E, Visentin M, Mairinger S, Römermann K, Stieger B, Kuntner C, Müller M, Langer O, Trauner M. The authors used positron emission tomography imaging to study the influence of norUDCA on hepatic disposition of the model Mrp4 substrate [(18)F]ciprofloxacin in wild-type and Mdr2(-/-) mice, a model of cholestasis. PubMed
  • Expert Opin Drug Metab Toxicol. 2016;12(3):245-51. Regulation of drug-metabolizing enzymes by local and systemic liver injuries. Guo Y, Hu B, Xie Y, Billiar TR, Sperry JL, Huang M, Xie W. PubMed
  • J Gastroenterol. 2016;51:808-18. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. Okushin K, Tsutsumi T, Enooku K, Fujinaga H, Kado A, Shibahara J, Fukayama M, Moriya K, Yotsuyanagi H, Koike K. PubMed
  • J Virol. 2015;89:11945-53. A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting Sodium Taurocholate Cotransporting Polypeptide. Kaneko M, Watashi K, Kamisuki S, Matsunaga H, Iwamoto M, Kawai F, Ohashi H, Tsukuda S, Shimura S, Suzuki R, Aizaki H, Sugiyama M, Park SY, Ito T, Ohtani N, Sugawara F, Tanaka Y, Mizokami M, Sureau C, Wakita T. PubMed
  • Dig Dis. 2015;33:388-96. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus. Yan H, Li W. PubMed
  • Pharm Res. 2015 Nov;32:3688-98. Protective effects of alisol B 23-acetate via farnesoid X receptor-mediated regulation of transporters and enzymes in estrogen-induced cholestatic liver injury in mice. Meng Q, Chen X, Wang C, Liu Q, Sun H, Sun P, Huo X, Liu Z, Yao J, Liu K. PubMed
  • Ann Hepatol. 2015;14:487-93.The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. Aguilar-Olivos NE, Carrillo-Córdova D, Oria-Hernández J, Sánchez-Valle V, Ponciano-Rodríguez G, Ramírez-Jaramillo M, Chablé-Montero F, Chávez-Tapia NC, Uribe M, Méndez-Sánchez N. PubMed
  • Diabetes. 2015;64:3305-13. Mechanism of altered metformin distribution in nonalcoholic steatohepatitis. Clarke JD, Dzierlenga AL, Nelson NR, Li H, Werts S, Goedken MJ, Cherrington NJ. PubMed
  • PLoS Pathog. 2015;11:e1004840. Hepatitis D virus jnfection of mice expressing human Sodium Taurocholate Co-transporting Polypeptide. He W, Ren B, Mao F, Jing Z, Li Y, Liu Y, Peng B, Yan H, Qi Y, Sun Y, Guo JT, Sui J, Wang F, Li W. PubMed
  • Pharmacol Ther. 2015;151:99-106. Nonalcoholic steatohepatitis in precision medicine: unraveling the factors that contribute to individual variability. Clarke JD, Cherrington NJ. Underlying liver diseases such as nonalcoholic steatohepatitis (NASH) alter drug absorption, distribution, metabolism, and excretion and must be considered in the implementation of precision medicine. There is still a profound need for clinical investigation into how NASH-associated changes in metabolism enzymes and transporters, affect the pharmacokinetics of individual drugs known to rely on these pathways for elimination. PubMed
  • Drug Metab Dispos. 2015;43:829-35. Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis. Canet MJ, Merrell MD, Hardwick RN, Bataille AM, Campion SN, Ferreira DW, Xanthakos SA, Manautou JE, A-Kader HH, Erickson RP, Cherrington NJ. PubMed
  • Top Antivir Med. 2015;23:92-6. Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment. Hill L. PubMed
  • Int J Clin Exp Pathol. 2015;8:5252-62.  Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis. Sticova E, Lodererova A, van de Steeg E, Frankova S, Kollar M, Lanska V, Kotalova R, Dedic T, Schinkel AH, Jirsa M. PubMed
  • J Hepatol. 2015;63:1023-37. Structural and functional hepatocyte polarity and liver disease. Gissen P, Arias IM. PubMed
  • Virology. 2015;481:34-42. Interleukin 6 inhibits HBV entry through NTCP down regulation. Bouezzedine F, Fardel O, Gripon P. PubMed
  • Cell Cycle. 2015;14:283-4. OCT1 in hepatic steatosis and thiamine disposition. Chen L, Yee SW, Giacomini KM. PubMed
  • Drug Metab Dispos. 2015;43:266-72. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis. Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ. PubMed
  • Hepatology. 2015;61:1251-60. The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Peng L, Zhao Q, Li Q, Li M, Li C, Xu T, Jing X, Zhu X, Wang Y, Li F, Liu R, Zhong C, Pan Q, Zeng B, Liao Q, Hu B, Hu ZX, Huang YS, Sham P, Liu J, Xu S, Wang J, Gao ZL, Wang Y. PubMed
  • Expert Opin Drug Metab Toxicol. 2015 Feb;11:273-93.  New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. van der Schoor LW, Verkade HJ, Kuipers F, Jonker JW. PubMed

Reviews from 2012 to 2014

  • Expert Opin Drug Metab Toxicol. 2014;10:1533-51. Effect of drug transporter pharmacogenetics on cholestasis. Dietrich CG, Geier PubMed
  • Expert Opin Drug Metab Toxicol. 2014;10:1209-19. Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis. Canet MJ, Cherrington NJ. PubMed
  • Drug Metab Dispos. 2014;42:546-60. The role of canalicular ABC transporters in cholestasis. Cuperus FJ, Claudel T, Gautherot J, Halilbasic E, Trauner M. PubMed
  • Drug Metab Dispos. 2014;42:675-84. IMAGING. The role of organic anion transporters in diagnosing liver diseases by magnetic resonance imaging. Pastor CM, Müllhaupt B, Stieger B. PubMed
  • J Hepatol. 2013;58:155-68. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. Halilbasic E, Claudel T, Trauner M. Hereditary and acquired defects of bile acid transporters are involved in the pathogenesis of several hepatobiliary disorders including cholestasis, gallstones, fatty liver disease and liver cancer, but also play a role in intestinal and metabolic disorders beyond the liver. PubMed
  • Clin Res Hepatol Gastroenterol. 2012;36:536-53. The bile salt export pump (BSEP) in health and disease. Kubitz R, Dröge C, Stindt J, Weissenberger K, Häussinger D. PubMed
  • Curr Drug Metab. 2012;13:1327-44. Drug disposition in pathophysiological conditions. Gandhi A, Moorthy B, Ghose R. PubMed
  • Front Biosci. 2012;17:1201-18. Localization status of hepatocellular transporters in cholestasis. Crocenzi FA, Zucchetti AE, Boaglio AC, Barosso IR, Sanchez Pozzi EJ, Mottino AD, Roma MG. PubMed